AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27422275 — intervention group
Group type: COMPARATOR
Intervention: Active waiting-list control group provided claims processing-related reading material, with telephone contact every 2 weeks for 10 weeks
Number of subjects: 180
Study 27422275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) programme
Number of subjects: 180
Study 27422275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 180
Study 27422275 — intervention group
Group type: COMPARATOR
Intervention: Active waiting-list control group
Number of subjects: 180
Study 24142751 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI) in patients with CRD
Number of subjects: 103
Study 22328727 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CLA supplementation
Number of subjects: 32
Study 22328727 — intervention group
Group type: COMPARATOR
Intervention: LPS challenge
Number of subjects: 32
Study 19237734 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐WREX
Number of subjects: 28
Study 19237734 — intervention group
Group type: COMPARATOR
Intervention: Tabletop exercise
Number of subjects: 28
Study 17557981 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography scans at multiple intervertebral positions (L2-L3, L3-L4, L4-L5)
Number of subjects: 24
Study 15333719 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong-gelling alginate
Number of subjects: 12
Study 15333719 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 12
Study 15333719 — intervention group
Group type: COMPARATOR
Intervention: Control (no added gelling agent)
Number of subjects: 12
Study 12587625 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ornidazole 30 mg/kg
Number of subjects: 175
Study 12587625 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ornidazole 25 mg/kg
Number of subjects: 175
Study 12587625 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ornidazole 20 mg/kg
Number of subjects: 175
Study 12587625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole 25 mg/kg per day for 5 days
Number of subjects: 175
Study 12587625 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 20 mg/kg per day for 7 days
Number of subjects: 175
Study 9691361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anti-D (200 micrograms)
Number of subjects: 11
Study 9691361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular anti-D (200 micrograms)
Number of subjects: 11
Study 9691361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intravenous and intramuscular anti-D
Number of subjects: 11
Study 7857498 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 3
Study 7857498 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 3
Study 7857498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 2527132 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g day‐1 of crystalline fructose in divided amounts as part of their isocaloric diet
Number of subjects: 13
Study 2527132 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetic diet (control)
Number of subjects: 13
Study 2527132 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g day‐1 of crystalline fructose
Number of subjects: 13
Study 402088 — intervention group
Group type: COMPARATOR
Intervention: 600 gm/24 hours glucose
Number of subjects: 12
Study 402088 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 gm/24 hours combination of glucose, fructose, and xylitol
Number of subjects: 12
Study 31649219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 2.4 ATA for 90 minutes in addition to conventional wound care
Number of subjects: 58
Study 31649219 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound care only
Number of subjects: 58
Study 31649219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 58
Study 29281988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (AS)
Number of subjects: 300
Study 29281988 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine (QNN)
Number of subjects: 300
Study 29281988 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 300
Study 29281988 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular genotyping
Number of subjects: 300
Study 29281988 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT administered
Number of subjects: 300
Study 29281988 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 300
Study 26005259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac + oral B vitamin
Number of subjects: 108
Study 26005259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac + oral vitamin E
Number of subjects: 108
Study 26005259 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac + placebo
Number of subjects: 108
Study 23503879 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNL after failed SWL (group 1)
Number of subjects: 62
Study 23503879 — intervention group
Group type: COMPARATOR
Intervention: PCNL as first treatment (group 2)
Number of subjects: 62
Study 21816019 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis Prevention and Self‐Management Course (OPSMC) (4 × 2.5 h)
Number of subjects: 146
Study 21816019 — intervention group
Group type: COMPARATOR
Intervention: One-session course (1 × 2.5 h)
Number of subjects: 146
Study 19451765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/d omega-3
Number of subjects: 27
Study 19451765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (R.P. Scherer)
Number of subjects: 27
Study 19451765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 17049642 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3532
Study 17049642 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 3532
Study 17049642 — intervention group
Group type: COMPARATOR
Intervention: Combined endpoint (CABG vs PCI)
Number of subjects: 3532
Study 17049642 — intervention group
Group type: COMPARATOR
Intervention: Combined endpoint (adjusted)
Number of subjects: 3532
Study 17049642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rates
Number of subjects: 3532
Study 15138617 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml coffee/day and a supplement of 200 microg folic acid/d
Number of subjects: 120
Study 15138617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12691171 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean or low-fat diets
Number of subjects: 300
Study 12691171 — intervention group
Group type: COMPARATOR
Intervention: Standard Western diet
Number of subjects: 300
Study 9650545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous terazosin (7.5 mg)
Number of subjects: 31
Study 9650545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terazosin (1 mg on day 1, 2 mg on day 2, and 5 mg on days 3 and 4)
Number of subjects: 31
Study 9650545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9650545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous terazosin (2.5 mg, 5 mg, or 7.5 mg)
Number of subjects: 31
Study 9650545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous terazosin
Number of subjects: 31
Study 9650545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terazosin
Number of subjects: 31
Study 8031158 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT group (300 mg/day for one year)
Number of subjects: 560
Study 8031158 — intervention group
Group type: COMPARATOR
Intervention: non-treatment group
Number of subjects: 560
Study 2688079 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam once-daily
Number of subjects: 307
Study 2688079 — intervention group
Group type: COMPARATOR
Intervention: 100 mg ketoprofen b.i.d.
Number of subjects: 307
Study 31968595 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative whey protein-infused carbohydrate loading and postoperative early oral feeding (CHO-P)
Number of subjects: 118
Study 28103110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers Supporting Success in Preschoolers: A Community Parent Education Program (Dialogic Reading)
Number of subjects: 126
Study 28103110 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 126
Study 27765310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound using the CardioProlific Genesis System followed by local administration of a liquid mixture of iopromide 370 and paclitaxel 1.0 μg/mm3
Number of subjects: 56
Study 27765310 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting balloons
Number of subjects: 56
Study 27858749 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (individualized home-based cycling and strengthening) for 6 months, followed by both groups receiving the intervention for an additional 12 months
Number of subjects: 14
Study 27858749 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 14
Study 22486580 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant monotherapy (ADM)
Number of subjects: 60
Study 22486580 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antidepressant therapy (CAD)
Number of subjects: 60
Study 20190720 — intervention group
Group type: EXPERIMENTAL
Intervention: C/T-13910 single nucleotide polymorphism genotyping assay
Number of subjects: 123
Study 20190720 — intervention group
Group type: COMPARATOR
Intervention: Comparison with existing data from other Italian regions
Number of subjects: 123
Study 19122339 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride
Number of subjects: 47
Study 15924540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling
Number of subjects: 45
Study 15924540 — intervention group
Group type: COMPARATOR
Intervention: Transurethral Macroplastique
Number of subjects: 45
Study 12931378 — intervention group
Group type: EXPERIMENTAL
Intervention: Feilinjian peroral liquid
Number of subjects: 203
Study 12931378 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 203
Study 10321528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin 0.2 mg/ml for 5 minutes
Number of subjects: 36
Study 10321528 — intervention group
Group type: COMPARATOR
Intervention: Postoperative mitomycin 0.2 mg/ml four times a day for 7 days
Number of subjects: 36
Study 8917000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 micrograms
Number of subjects: 100
Study 8917000 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 200 mg
Number of subjects: 100
Study 1886479 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution at 26 g.h(‐1)
Number of subjects: 10
Study 1886479 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution at 52 g.h(‐1)
Number of subjects: 10
Study 1886479 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution at 78 g.h(‐1)
Number of subjects: 10
Study 1886479 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 10
Study 1886479 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate feeding
Number of subjects: 10
Study 6814928 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion at 3.4 micrograms/min
Number of subjects: 5
Study 6814928 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion at 7.5 micrograms/min
Number of subjects: 5
Study 6814928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30921502 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly 28.2-μg teriparatide injections
Number of subjects: 100
Study 30921502 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly 56.5-μg teriparatide injections
Number of subjects: 100
Study 30851316 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) during motor tasks
Number of subjects: 24
Study 30851316 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) during tri session paradigm
Number of subjects: 24
Study 30851316 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 28645287 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 1717
Study 25899989 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g/kg/day)
Number of subjects: 0
Study 25899989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24353120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation with argon plasma coagulation (APC)
Number of subjects: 63
Study 24353120 — intervention group
Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 63
Study 23211896 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted formocresol (DFC)
Number of subjects: 168
Study 23211896 — intervention group
Group type: COMPARATOR
Intervention: Gray mineral trioxide aggregate (GMTA)
Number of subjects: 168
Study 18774751 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-C
Number of subjects: 209
Study 18774751 — intervention group
Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 209
Study 17912165 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Percutaneous Coronary Intervention (PCI)
Number of subjects: 0
Study 17912165 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (especially abciximab)
Number of subjects: 0
Study 17912165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel with aspirin)
Number of subjects: 0
Study 17912165 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stents (BMS)
Number of subjects: 0
Study 17912165 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 17912165 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 17912165 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 17912165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-coronary (IC) injection of drugs
Number of subjects: 0
Study 16274414 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D (Cardiac Resynchronization Therapy with Defibrillator)
Number of subjects: 0
Study 12144585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.d.s. (n=9)
Number of subjects: 19
Study 12144585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 19
Study 12144585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.d.s.
Number of subjects: 19
Study 12144585 — intervention group
Group type: COMPARATOR
Intervention: Cisapride 10 mg t.d.s. and Placebo
Number of subjects: 19
Study 10556006 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 35
Study 10150860 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic options that attempt to moderate intraocular pressure (IOP)
Number of subjects: 0
Study 10150860 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic options that attempt to alter blood flow
Number of subjects: 0
Study 1976937 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist clinic treatment
Number of subjects: 40
Study 1976937 — intervention group
Group type: COMPARATOR
Intervention: General practitioner (GP) treatment
Number of subjects: 40
Study 7468115 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine 0.75%
Number of subjects: 60
Study 7468115 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with thiopentone, fentanyl, pancuronium, N2O/O2
Number of subjects: 60
Study 30915972 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-play activities
Number of subjects: 49
Study 30915972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 29912061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg oral)
Number of subjects: 36
Study 29912061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27651843 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Treatment (OMT)
Number of subjects: 14
Study 27651843 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 14
Study 24561029 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized measurement of MEWS three times daily
Number of subjects: 3585
Study 24561029 — intervention group
Group type: COMPARATOR
Intervention: Control group measuring MEWS when clinically indicated
Number of subjects: 3585
Study 22308559 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS)
Number of subjects: 28
Study 22308559 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental Treatment (NDT/Bobath)
Number of subjects: 28
Study 21048211 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of oral aloe vera powder
Number of subjects: 16
Study 21048211 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study 17194824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flucytosine at 100 mg/kg/day
Number of subjects: 32
Study 17194824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flucytosine at 100 mg/kg/day
Number of subjects: 32
Study 17194824 — intervention group
Group type: COMPARATOR
Intervention: Intravenous flucytosine
Number of subjects: 32
Study 17194824 — intervention group
Group type: COMPARATOR
Intervention: Oral flucytosine
Number of subjects: 32
Study 17194824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (oral and intravenous)
Number of subjects: 32
Study 15256418 — intervention group
Group type: COMPARATOR
Intervention: Twins after assisted conception
Number of subjects: 3393
Study 15256418 — intervention group
Group type: EXPERIMENTAL
Intervention: Children conceived by ICSI
Number of subjects: 3393
Study 11603960 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra-containing potato chips
Number of subjects: 14
Study 11603960 — intervention group
Group type: COMPARATOR
Intervention: Regular fat-containing potato chips (placebo)
Number of subjects: 14
Study 9440412 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises in their homes three times a week for 10 weeks
Number of subjects: 100
Study 9440412 — intervention group
Group type: COMPARATOR
Intervention: Normal activities
Number of subjects: 100
Study 8015127 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded reviewers
Number of subjects: 4
Study 8015127 — intervention group
Group type: COMPARATOR
Intervention: Nonblinded reviewers
Number of subjects: 4
Study 8015127 — intervention group
Group type: COMPARATOR
Intervention: Editors
Number of subjects: 4
Study 2492414 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted Smead‐Jones far‐far‐near‐near sutures
Number of subjects: 2
Study 2492414 — intervention group
Group type: COMPARATOR
Intervention: Running sutures
Number of subjects: 2
Study 2492414 — intervention group
Group type: EXPERIMENTAL
Intervention: Running #1 polydioxanone (PDS) suture
Number of subjects: 2
Study 2492414 — intervention group
Group type: COMPARATOR
Intervention: #1 polypropylene (Prolene) suture
Number of subjects: 2
Study 1102614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alice strain vaccine intranasally
Number of subjects: 199
Study 1102614 — intervention group
Group type: COMPARATOR
Intervention: Bivalent inactivated influenza vaccine intramuscularly
Number of subjects: 199
Study 1102614 — intervention group
Group type: COMPARATOR
Intervention: Placebo intranasally
Number of subjects: 199
Study 31044450 — intervention group
Group type: EXPERIMENTAL
Intervention: HVI injection with corticosteroid
Number of subjects: 28
Study 31044450 — intervention group
Group type: COMPARATOR
Intervention: HVI injection without corticosteroid
Number of subjects: 28
Study 25416688 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank preserving structural failure time models (RPSFTM)
Number of subjects: 0
Study 25416688 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative parameter estimation methods
Number of subjects: 0
Study 25416688 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse probability of censoring weights method
Number of subjects: 0
Study 25416688 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural nested models
Number of subjects: 0
Study 25416688 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified two-stage Weibull method
Number of subjects: 0
Study 26225498 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation with PEEP (positive inspiratory pressure: 12 cmH2O, PEEP: 6 cmH2O)
Number of subjects: 0
Study 26225498 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation without PEEP (positive inspiratory pressure: 12 cmH2O)
Number of subjects: 0
Study 26225498 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 0
Study 21964284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pavlovian safety signal training
Number of subjects: 0
Study 21964284 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental avoidance response training
Number of subjects: 0
Study 21964284 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported shock expectancies
Number of subjects: 0
Study 21964284 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance responses
Number of subjects: 0
Study 22168568 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Aspirin for 3 years
Number of subjects: 0
Study 22168568 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 years
Number of subjects: 0
Study 19169631 — intervention group
Group type: EXPERIMENTAL
Intervention: DrotAA (recombinant activated protein C)
Number of subjects: 602
Study 19169631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 16863391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 13
Study 14616153 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 26
Study 14616153 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 26